Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
The CDC's $1.3 billion Division of HIV Prevention is tasked with tracking infections across the United States.
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback